Developer docs
API playgroundTry for free, no card

Search company profiles

Ollin Biosciences

Full company profile

uuid00004dt

Namestring
Ollin Biosciences
Legal namestring
Ollin Biosciences, Inc.
Websiteurl
ollin.bio
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Ollin Biosciences is a clinical-stage biopharmaceutical company founded in 2023 and headquartered in Austin, Texas, that develops bispecific antibody therapies for vision-threatening eye diseases. Its portfolio comprises two core programs: OLN324, a higher-potency, small-format VEGF/Ang2 bispecific antibody advancing to Phase 3 for diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD), and OLN102, a first-in-class IGF-1R/TSHR bispecific antibody in IND-enabling stage for thyroid eye disease. The company emerged from stealth in September 2025 and is led by Co-Founder and CEO Jason Ehrlich, M.D., Ph.D., a former Genentech executive, supported by a nine-person executive team covering translational sciences, biology, clinical development, clinical operations, portfolio, and corporate development.

In a 164-patient Phase 1b JADE head-to-head study, OLN324 demonstrated faster and greater retinal anatomy improvements than faricimab (Vabysmo), including approximately 50% greater reductions in pigment epithelial detachment thickness in wet AMD, a +2.2 letter visual acuity advantage at week 20, 93% of DME patients on 4mg completing 12 weeks without retreatment versus 89% on faricimab, nearly 90% achieving absence of DME at week 12 versus 57% for faricimab, and zero cases of intraocular inflammation. Both the FDA and EMA have provided constructive feedback on the Phase 3 trial design, which is planned to initiate in the second half of 2026.

Ollin has raised approximately $430 million in private capital, comprising a $100 million round in September 2025 and an oversubscribed $330 million Series B in June 2026 co-led by TCGX and ARCH Venture Partners, with participation from a16z Bio+Health, Blackstone, CPP Investments, RA Capital Management, Mubadala Capital, Monograph Capital, and T. Rowe Price Investment Management. In June 2026, Ollin entered a strategic development and commercialization partnership with Innovent Biologics for IBI324 (OLN324), enabling Phase 3 expansion into China and South Korea. As a clinical-stage company with no commercialized products, Ollin generates no product revenue and addresses an estimated $15 billion worldwide retina therapeutics market opportunity, with a combined addressable market across OLN324, IBI363, and IBI343 exceeding $60 billion per company-supplied commentary.

Short descriptiontext

Ollin Biosciences is a clinical-stage biopharmaceutical company developing bispecific antibody therapies for vision-threatening eye diseases, including OLN324 (VEGF/Ang2) for diabetic macular edema and wet AMD, and OLN102 (IGF-1R/TSHR) for thyroid eye disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
bispecific antibody therapeutics, ophthalmic drug development, clinical-stage biopharmaceuticals, retinal disease therapies, biologics pipeline development
Industry2 codes
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Ophthalmic Biopharmaceuticals
Social media profiles1 record
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ollin Biosciences is a clinical-stage biopharmaceutical company developing a pipeline of proprietary bispecific antibody drug candidates for vision-threatening eye diseases. Its lead asset OLN324 is a higher-potency, small-format VEGF/Ang2 bispecific antibody in Phase 3 development for diabetic macular edema and wet age-related macular degeneration, and its second asset OLN102 is a first-in-class IGF-1R/TSHR bispecific antibody in IND-enabling stage for thyroid eye disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 93% of patients on OLN324 4mg completed 12 weeks without retreatment vs 89% on faricimab in DME
+4 more records
Product overview1 text field

Ollin Biosciences is a clinical-stage biopharmaceutical company developing a differentiated pipeline of drug candidates for vision-threatening eye diseases. The company's portfolio consists of two core therapeutic programs: OLN324, a next-generation VEGF/Ang2 bispecific antibody in Phase 3 for diabetic macular edema and wet age-related macular degeneration, and OLN102, a first-in-class IGF-1R/TSHR bispecific antibody in IND-enabling stage for thyroid eye disease. Both candidates build from validated biology to target serious ophthalmic conditions.

Product and service2 records
1OLN324
CategoryOphthalmic Biologics / Bispecific Antibody Therapeutic
Description

Higher potency, small format VEGF/Ang2 bispecific antibody in Phase 3 development for diabetic macular edema and wet age-related macular degeneration, developed for patients with vision-threatening retinal diseases and for biopharmaceutical partners seeking a differentiated ophthalmology biologic.

2OLN102
CategoryOphthalmic Biologics / Bispecific Antibody Therapeutic
Description

First-in-class IGF-1R/TSHR bispecific antibody in IND-enabling stage for thyroid eye disease, developed for patients with limited treatment options in this ophthalmic indication.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-25
Description

Strategic partnership with Innovent Biologics for the development and commercialization of IBI324 (OLN324). The partnership enables global Phase 3 trials including China and South Korea, with OLN324 being advanced as a next-generation VEGF/Ang2 bispecific antibody for diabetic macular edema and wet age-related macular degeneration.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Developer of faricimab (Vabysmo), the established VEGF/Ang2 bispecific antibody that OLN324 was designed to beat in head-to-head trials. Most direct large-pharma incumbent competing for the same retina therapeutics market.

TypeBroad incumbent
Description

Markets Eylea and Eylea HD (aflibercept), the dominant anti-VEGF franchise in DME and wet AMD. Represents the entrenched standard of care that any new retina therapeutic must displace.

TypeDirect peer
Description

Clinical-stage biotech developing novel biologics for retinal diseases, including ABC platform candidates targeting VEGF-mediated ophthalmology indications — directly comparable clinical-stage anti-VEGF developer.

TypeDirect peer
Description

Clinical-stage company developing sozinibercept, a novel anti-VEGF-C/D therapy for wet AMD. Competes in the same retinal vascular indication space as Ollin's OLN324.

TypeEmerging player
Description

Gene therapy company developing ADVM-022 (intravitreal aflibercept gene therapy) for wet AMD and DME — addresses the same patient population with a different therapeutic modality targeting anti-VEGF biology.

TypeBroad incumbent
Description

Markets Syfovre (pegcetacoplan) for geographic atrophy; broader ophthalmology commercial player. While focused on complement rather than VEGF, Apellis represents a competing ophthalmology biopharmaceutical company with commercial infrastructure.

TypeEmerging player
Description

Developed LYTENAVA (ONS-5010), an ophthalmic formulation of bevacizumab for wet AMD. Competes for share of retina therapeutics market with a biosimilar-adjacent anti-VEGF approach.

TypeEmerging player
Description

Clinical and commercial-stage ophthalmology company developing sustained-release therapies including anti-VEGF programs for retinal disease. Directly comparable clinical-stage retina therapeutics developer.

TypeEmerging player
Description

Clinical-stage biotech developing complement-based therapies for retinal diseases including geographic atrophy. Comparable clinical-stage ophthalmology biopharmaceutical company pursuing novel mechanisms in serious eye diseases.

TypeBroad incumbent
Description

Markets ophthalmology biosimilars including Cimerli (ranibizumab biosimilar) and is developing additional retina biosimilars. Competes on price in the same anti-VEGF retina therapeutics market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ollin Biosciences

Ophthalmic Biopharmaceuticalsollin.bio

Ollin Biosciences is a clinical-stage biopharmaceutical company developing bispecific antibody therapies for vision-threatening eye diseases, including OLN324 (VEGF/Ang2) for diabetic macular edema and wet AMD, and OLN102 (IGF-1R/TSHR) for thyroid eye disease.

What Ollin Biosciences does

Ollin Biosciences is a clinical-stage biopharmaceutical company founded in 2023 and headquartered in Austin, Texas, that develops bispecific antibody therapies for vision-threatening eye diseases. Its portfolio comprises two core programs: OLN324, a higher-potency, small-format VEGF/Ang2 bispecific antibody advancing to Phase 3 for diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD), and OLN102, a first-in-class IGF-1R/TSHR bispecific antibody in IND-enabling stage for thyroid eye disease. The company emerged from stealth in September 2025 and is led by Co-Founder and CEO Jason Ehrlich, M.D., Ph.D., a former Genentech executive, supported by a nine-person executive team covering translational sciences, biology, clinical development, clinical operations, portfolio, and corporate development.

In a 164-patient Phase 1b JADE head-to-head study, OLN324 demonstrated faster and greater retinal anatomy improvements than faricimab (Vabysmo), including approximately 50% greater reductions in pigment epithelial detachment thickness in wet AMD, a +2.2 letter visual acuity advantage at week 20, 93% of DME patients on 4mg completing 12 weeks without retreatment versus 89% on faricimab, nearly 90% achieving absence of DME at week 12 versus 57% for faricimab, and zero cases of intraocular inflammation. Both the FDA and EMA have provided constructive feedback on the Phase 3 trial design, which is planned to initiate in the second half of 2026.

Ollin has raised approximately $430 million in private capital, comprising a $100 million round in September 2025 and an oversubscribed $330 million Series B in June 2026 co-led by TCGX and ARCH Venture Partners, with participation from a16z Bio+Health, Blackstone, CPP Investments, RA Capital Management, Mubadala Capital, Monograph Capital, and T. Rowe Price Investment Management. In June 2026, Ollin entered a strategic development and commercialization partnership with Innovent Biologics for IBI324 (OLN324), enabling Phase 3 expansion into China and South Korea. As a clinical-stage company with no commercialized products, Ollin generates no product revenue and addresses an estimated $15 billion worldwide retina therapeutics market opportunity, with a combined addressable market across OLN324, IBI363, and IBI343 exceeding $60 billion per company-supplied commentary.

Ollin Biosciences firmographics

Firmographics
Name
Ollin Biosciences
Legal name
Ollin Biosciences, Inc.
Website
https://ollin.bio
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
Ollin Biosciences is a clinical-stage biopharmaceutical company developing bispecific antibody therapies for vision-threatening eye diseases, including OLN324 (VEGF/Ang2) for diabetic macular edema and wet AMD, and OLN102 (IGF-1R/TSHR) for thyroid eye disease.
Ownership category
akta.pro rank

Ollin Biosciences industry classification

Industry
Product category
Ophthalmic Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals

Keywords

  • Bispecific antibody therapeutics
  • Ophthalmic drug development
  • Clinical-stage biopharmaceuticals
  • Retinal disease therapies
  • Biologics pipeline development

Where Ollin Biosciences is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Markets served

Ollin Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels3 records

Ollin Biosciences product offering

Product offering

Core offering

Ollin Biosciences is a clinical-stage biopharmaceutical company developing a pipeline of proprietary bispecific antibody drug candidates for vision-threatening eye diseases. Its lead asset OLN324 is a higher-potency, small-format VEGF/Ang2 bispecific antibody in Phase 3 development for diabetic macular edema and wet age-related macular degeneration, and its second asset OLN102 is a first-in-class IGF-1R/TSHR bispecific antibody in IND-enabling stage for thyroid eye disease.

Product overview

Ollin Biosciences is a clinical-stage biopharmaceutical company developing a differentiated pipeline of drug candidates for vision-threatening eye diseases. The company's portfolio consists of two core therapeutic programs: OLN324, a next-generation VEGF/Ang2 bispecific antibody in Phase 3 for diabetic macular edema and wet age-related macular degeneration, and OLN102, a first-in-class IGF-1R/TSHR bispecific antibody in IND-enabling stage for thyroid eye disease. Both candidates build from validated biology to target serious ophthalmic conditions.

Differentiator

Problem solved

Functional benefit

Products and services

  • OLN324 Higher potency, small format VEGF/Ang2 bispecific antibody in Phase 3 development for diabetic macular edema and wet age-related macular degeneration, developed for patients with vision-threatening retinal diseases and for biopharmaceutical partners seeking a differentiated ophthalmology biologic.
  • OLN102 First-in-class IGF-1R/TSHR bispecific antibody in IND-enabling stage for thyroid eye disease, developed for patients with limited treatment options in this ophthalmic indication.

Quantifiable outcome

  • 93% of patients on OLN324 4mg completed 12 weeks without retreatment vs 89% on faricimab in DME
  • +4 more outcomes

Companies that use Ollin Biosciences

Customer profile

Segments1 record

Ideal customer profiles1 record

Ollin Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Ollin Biosciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Innovent BiologicscoreStrategic or Co-development Partner · 25 June 2026Strategic partnership with Innovent Biologics for the development and commercialization of IBI324 (OLN324). The partnership enables global Phase 3 trials including China and South Korea, with OLN324 being advanced as a next-generation VEGF/Ang2 bispecific antibody for diabetic macular edema and wet age-related macular degeneration.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Ollin Biosciences competitors and assessment

Company assessment

Broad incumbents

  • Genentech (Roche): Developer of faricimab (Vabysmo), the established VEGF/Ang2 bispecific antibody that OLN324 was designed to beat in head-to-head trials. Most direct large-pharma incumbent competing for the same retina therapeutics market.
  • Regeneron Pharmaceuticals: Markets Eylea and Eylea HD (aflibercept), the dominant anti-VEGF franchise in DME and wet AMD. Represents the entrenched standard of care that any new retina therapeutic must displace.
  • Apellis Pharmaceuticals: Markets Syfovre (pegcetacoplan) for geographic atrophy; broader ophthalmology commercial player. While focused on complement rather than VEGF, Apellis represents a competing ophthalmology biopharmaceutical company with commercial infrastructure.
  • Coherus BioSciences: Markets ophthalmology biosimilars including Cimerli (ranibizumab biosimilar) and is developing additional retina biosimilars. Competes on price in the same anti-VEGF retina therapeutics market.

Direct peers

  • Kodiak Sciences: Clinical-stage biotech developing novel biologics for retinal diseases, including ABC platform candidates targeting VEGF-mediated ophthalmology indications — directly comparable clinical-stage anti-VEGF developer.
  • Opthea: Clinical-stage company developing sozinibercept, a novel anti-VEGF-C/D therapy for wet AMD. Competes in the same retinal vascular indication space as Ollin's OLN324.

Emerging players

  • Adverum Biotechnologies: Gene therapy company developing ADVM-022 (intravitreal aflibercept gene therapy) for wet AMD and DME — addresses the same patient population with a different therapeutic modality targeting anti-VEGF biology.
  • Outlook Therapeutics: Developed LYTENAVA (ONS-5010), an ophthalmic formulation of bevacizumab for wet AMD. Competes for share of retina therapeutics market with a biosimilar-adjacent anti-VEGF approach.
  • Ocular Therapeutix: Clinical and commercial-stage ophthalmology company developing sustained-release therapies including anti-VEGF programs for retinal disease. Directly comparable clinical-stage retina therapeutics developer.
  • Annexon: Clinical-stage biotech developing complement-based therapies for retinal diseases including geographic atrophy. Comparable clinical-stage ophthalmology biopharmaceutical company pursuing novel mechanisms in serious eye diseases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Ollin Biosciences social profiles

Digital presence

Ollin Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ollin Biosciences leadership team

Management profile

Number of profiles

Profiles9 records

Ollin Biosciences funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ollin Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ollin Biosciences

What does Ollin Biosciences do?

Ollin Biosciences is a clinical-stage biopharmaceutical company developing a pipeline of proprietary bispecific antibody drug candidates for vision-threatening eye diseases. Its lead asset OLN324 is a higher-potency, small-format VEGF/Ang2 bispecific antibody in Phase 3 development for diabetic macular edema and wet age-related macular degeneration, and its second asset OLN102 is a first-in-class IGF-1R/TSHR bispecific antibody in IND-enabling stage for thyroid eye disease.

Is Ollin Biosciences a public or private company?

Ollin Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ollin Biosciences founded?

Ollin Biosciences was founded in 2023. It employs 11 to 50 people.

Where is Ollin Biosciences based?

Ollin Biosciences is headquartered in Austin, United States, in the North America region.

Who are Ollin Biosciences's main competitors?

Broad incumbents on record are Genentech (Roche), Regeneron Pharmaceuticals, Apellis Pharmaceuticals and Coherus BioSciences. Direct peers are Kodiak Sciences and Opthea. Emerging players are Adverum Biotechnologies, Outlook Therapeutics, Ocular Therapeutix and Annexon.

Does Ollin Biosciences have an API?

No public API is recorded for Ollin Biosciences.

What industry is Ollin Biosciences in?

Ollin Biosciences's product category is Ophthalmic Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooThis week in charts: Biotech investors’ China bets are already paying offSix China-linked biotech startups were acquired or went public in 2026, including Ouro Medicines, Candid Therapeutics, and Ollin Biosciences in billion-dollar deals. Summit Therapeutics' stock fell after the FDA rejected its initial approval request for a lung cancer drug, sending shares back to two-year-old levels.36krPost Anti-VEGF Era: The $10-Billion Hidden Battle in the Global Ocular Fundus Treatment FieldJohnson & Johnson acquired Ollin Biosciences for up to $3.325 billion, adding two bispecific antibody pipelines. OLN324, a VEGF/Ang2 bispecific, is in Phase III for wet AMD and DME, with head-to-head data showing superior retinal fluid control versus Vabysmo. The acquisition targets the $100B fundus drug market.PedailyFind a top team, the pharmaceutical second brother makes a big profit.Johnson acquired Ollin Biosciences for $2.2 billion upfront plus up to $1.125 billion in milestones, citing its IBI324 and OLN102 assets. The deal highlights that the management team's clinical design and regulatory progress, not just asset quality, drove the exit. The article uses this as a framework for evaluating biotech Newco partners.医药魔方-致力于数据赋能医药创新,助力高效决策与数智化转型J&J to Acquire Ollin for Up to USD 3.325bn for VEGF-A×Ang2 BsAbJohnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront plus up to $1.125 billion in milestones, with $750 million in development funding from Blackstone. The deal targets OLN324, a bispecific antibody for retinal diseases, which showed superior efficacy over faricimab in early data.Simply Wall StIs Johnson & Johnson (JNJ) Fully Valued Following Its Reported Ollin Biosciences Talks?Johnson & Johnson is negotiating a potential Ollin Biosciences acquisition valued at up to $3.4b, with shares up 36.27% year-to-date. The stock trades at a 42.3x P/E versus a 17.1x industry average, raising valuation concerns. Investors weigh pipeline growth against MedTech and legal risks.MarketScreenerHealth Care Down, but not by Much, Amid Deal Activity -- Health Care RoundupHealth-care stocks fell less than the broad market amid deal activity, including Johnson & Johnson's $2.2 billion acquisition of Ollin Biosciences and Eli Lilly's up-to-$1.5 billion deal to buy Calytrix Bio. The deals involve biotech firms developing eye-care and rare blood cancer treatments.MorningstarHealth Care Down, but not by Much, Amid Deal Activity — Health Care RoundupHealth-care stocks fell less than the broad market amid deal activity, with Johnson & Johnson agreeing to buy Ollin Biosciences for an initial $2.2 billion and Eli Lilly agreeing to pay up to $1.5 billion for Calytrix Bio. The deals involve funding for Ollin's lead eye-care product and Calytrix's rare blood cancer treatments.MarketWatchHealth Care Down, but not by Much, Amid Deal Activity -- Health Care RoundupHealth-care stocks fell less than the broad market amid deal activity. Johnson & Johnson agreed to buy Ollin Biosciences for an initial $2.2 billion, and Eli Lilly agreed to pay up to $1.5 billion for Calytrix Bio.MarketScreenerJohnson & Johnson entered into a definitive agreement to acquire Ollin Biosciences, Inc. for $3.3 billion.Johnson & Johnson entered a definitive agreement to acquire Ollin Biosciences for $3.3 billion on November 16, 2026, with $2.2 billion in cash and potential milestone payments up to $1.13 billion. The deal is expected to close before the end of 2026, subject to regulatory approvals.TradingViewJ&J Pushes Into Retinal Disease With $2.2 Billion Ollin DealJohnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront plus up to $1.125 billion in milestones. The deal adds OLN324, a bispecific antibody in Phase 3 for wet AMD and diabetic macular edema. Blackstone will pay $750 million over several years to fund development, with closing expected before end of 2026.